Financial Data and Key Metrics Changes - The company ended Q4 2025 with approximately $292.3 million in cash and marketable securities, remaining debt-free with about 31.3 million shares outstanding [32] - Q4 net product revenues were approximately $1.6 million, with over 20,000 monthly paid and filled prescriptions [32] - Total Q4 operating expenses were approximately $40 million, with a net cash burn of about $32 million [33][34] - The net loss per share for Q4 was $1.16, compared to a net loss per share of $0.46 in Q4 2024 [35] Business Line Data and Key Metrics Changes - The company sold over 45,000 boxes of LNZ100, prescribed by more than 10,000 eye care professionals [7] - The product is showing strong refill behavior, with patients moving from one-month to three-month prescriptions [47] - The top 1,000 prescribers are filling over 40% more scripts per doctor compared to a comparable point in the VUITY launch [8][22] Market Data and Key Metrics Changes - Presbyopia affects approximately 128 million people in the United States, representing a significant market opportunity [6][18] - The company is seeing a broad base of prescribing physicians, with over 55% of ECPs having written VIZZ multiple times [20] Company Strategy and Development Direction - The company aims to build a new treatment category for presbyopia, focusing on accelerating adoption through disciplined execution and investment [16][40] - The sales force is expanding from 88 to 117 representatives to increase call frequency and coverage of eye care professionals [12][23] - The direct-to-consumer campaign is designed to build consumer awareness and drive demand for VIZZ [14][26] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the early signals of patient persistence and the growing base of prescribing physicians [40] - The company expects to see an acceleration in new patient starts as prescriber habits build and consumer awareness grows [16][40] - The operational actions taken in the field are aimed at enhancing adoption and integrating VIZZ into everyday clinical practice [12][16] Other Important Information - The company has submitted multiple NDA applications for international approvals, anticipating potential approvals in early 2027 [39] - The direct-to-consumer campaign has resulted in a significant increase in website traffic, with spikes of up to 10 times normal levels during national activations [14][26] Q&A Session Summary Question: Can you discuss the sampling dynamic to NRX and retention? - Management feels confident about the adoption, noting strong early signals of refill behavior and patient commitment to the product [45][47] Question: What investments are being made to broaden patient demand? - The focus is on digital advertising and optimizing media placements to effectively reach target demographics [49][50] Question: What percentage of prescribers are from the initial target group versus inbounds from patient demand? - The company is seeing growth in prescribers from both target and non-target groups, with many new prescribers who had not previously written for VUITY now engaging with VIZZ [52][53] Question: Can you elaborate on the behavior of the top prescribers? - The top prescribers are effectively integrating VIZZ into their practices and are more comfortable with new technologies, leading to higher prescription rates [59][62]

Financial Data and Key Metrics Changes - The company ended 2025 with approximately $292.3 million in cash and marketable securities, remaining debt-free with about 31.3 million shares outstanding [32][33] - Q4 2025 net product revenues were approximately $1.6 million, with over 20,000 monthly paid and filled prescriptions [33] - Total Q4 operating expenses were approximately $40 million, with a net cash burn of about $32 million [34][35] - The net loss per share in Q4 2025 was $1.16, compared to a net loss per share of $0.46 in Q4 2024 [37] Business Line Data and Key Metrics Changes - The company sold over 45,000 boxes of LNZ100, prescribed by more than 10,000 eye care professionals, indicating strong adoption [7][26] - The product is showing encouraging refill behavior, with patients moving from one-month to three-month prescriptions [48][76] Market Data and Key Metrics Changes - Presbyopia affects approximately 128 million people in the United States, representing a significant market opportunity for the company [6][18] - The company is seeing a broad base of prescribing physicians, with over 55% of ECPs having written VIZZ multiple times [21][22] Company Strategy and Development Direction - The company aims to build a new treatment category for presbyopia, focusing on accelerating adoption through enhanced physician messaging and expanding the sales force [12][19] - The direct-to-consumer campaign launched in January is expected to take at least two quarters to translate into prescription trends, with early indicators showing positive engagement [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the product's effectiveness and the encouraging early signals of patient persistence, indicating a strong foundation for future growth [16][42] - The company is focused on executing its strategy to build a blockbuster category, leveraging both physician and consumer adoption [16][42] Other Important Information - The company plans to maintain a significant portion of its operating expenses towards sales and marketing, targeting approximately 75%-80% [39] - The company is advancing its global expansion strategy, with potential approvals in multiple geographies anticipated in early 2027 [40][41] Q&A Session Questions and Answers Question: Can you discuss the sampling dynamic to NRX and retention? - Management feels good about the NRX and refill dynamic, noting that patients who purchase continue to use the product, with encouraging refill rates observed [46][48] Question: What investments are being made to broaden patient demand? - The focus is on digital advertising and optimizing media placements to effectively reach target demographics, with a selective approach to linear TV advertising in key markets [50][51] Question: What percentage of prescribers are from the initial target group versus inbounds from patient demand? - The company has expanded its target group from 12,000 to 15,000 ECPs, with many new prescribers being those who had never written Vuity before [53][54] Question: Can you provide insights on the behavior of the top 1,000 prescribers? - The top prescribers are more comfortable with new technologies and have successfully integrated VIZZ into their patient discussions, setting appropriate expectations for its use [59][63]

Financial Data and Key Metrics Changes - The company ended Q4 2025 with approximately $292.3 million in cash and marketable securities, remaining debt-free with about 31.3 million shares outstanding [32] - Q4 net product revenues were approximately $1.6 million, with over 20,000 monthly paid and filled prescriptions [32] - Operating expenses for Q4 totaled approximately $40 million, with a net cash burn of about $32 million [33][34] - The net loss per share for Q4 was $1.16, compared to a net loss per share of $0.46 in Q4 2024 [35] Business Line Data and Key Metrics Changes - The launch of LNZ100 has resulted in over 45,000 boxes sold, prescribed by more than 10,000 eye care professionals [5][26] - The product is showing strong refill behavior, with patients moving from one-month to three-month prescriptions [48][72] Market Data and Key Metrics Changes - Presbyopia affects approximately 128 million people in the U.S., representing a significant market opportunity [18] - The company is seeing a broad base of prescribing physicians, with over 55% of doctors having written VIZZ multiple times [20] Company Strategy and Development Direction - The company aims to build a new treatment category for presbyopia, focusing on increasing physician adoption and consumer awareness [16][19] - The sales force is expanding from 88 to 117 representatives to increase call frequency and broaden coverage of eye care professionals [24][25] - A direct-to-consumer campaign featuring Sarah Jessica Parker has been launched to drive consumer engagement [27][28] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the product's performance and the potential for a large, under-penetrated market [16][30] - The company expects to see an acceleration in new patient starts as prescriber habits build and consumer awareness grows [41] Other Important Information - The company has made significant progress in global expansion, with multiple NDA submissions anticipated in early 2027 [39][40] - The direct-to-consumer campaign is showing early positive indicators, with website traffic increasing significantly [13][28] Q&A Session Summary Question: Can you discuss the sampling dynamic to NRX and retention? - Management is encouraged by refill rates and believes the sampling strategy is effective, with patients returning for reorders [46][48] Question: What investments are being made to broaden patient demand? - The focus is on digital advertising and optimizing media placements to effectively reach target demographics [50][51] Question: What percentage of prescribers are from the initial target group versus inbounds from patient demand? - The company is seeing growth in prescribers from both targeted and non-targeted groups, with many new prescribers who had not previously written Vuity now adopting VIZZ [52][53] Question: Can you elaborate on the behavior of the top prescribers? - The top prescribers are effectively integrating VIZZ into their practices and are comfortable offering it to a broader patient population [59][63] Question: How are you planning to correct misconceptions about VIZZ's target population? - The company is actively working to educate prescribers on the broader applicability of VIZZ beyond early presbyopes [64]

Core Viewpoint - Ally Bridge Group NY LLC significantly reduced its stake in LENZ Therapeutics by 48.9% during the third quarter, indicating a potential shift in investment strategy or confidence in the company [2] Institutional Investment Activity - Versant Venture Management LLC acquired a new stake in LENZ Therapeutics valued at approximately $123.76 million during the third quarter [3] - Adage Capital Partners GP L.L.C. increased its stake by 108.8% in the second quarter, now holding 1,122,738 shares worth $32.91 million after acquiring an additional 585,000 shares [3] - Franklin Resources Inc. raised its position by 6,756.1% in the third quarter, owning 587,084 shares valued at $27.35 million after acquiring 578,521 shares [3] - UBS Group AG increased its stake by 36.3% in the third quarter, now owning 1,201,616 shares valued at $55.97 million after acquiring 320,135 shares [3] - Hedge funds and institutional investors collectively own 54.32% of LENZ Therapeutics [3] Analyst Ratings - HC Wainwright maintained a "buy" rating for LENZ Therapeutics [4] - Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Zacks Research downgraded the stock from "strong-buy" to "hold" [4] - Weiss Ratings reiterated a "sell (d-)" rating [4] - William Blair reissued an "outperform" rating [4] - The consensus rating for LENZ Therapeutics is "Moderate Buy" with a price target of $56.40 [4] Stock Performance - LENZ Therapeutics opened at $12.15, with a market cap of $380.17 million [5] - The stock has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $25.99 [5] - The one-year low for the stock is $11.21, while the one-year high is $50.40 [5] - The company has a P/E ratio of -5.76 and a beta of 0.52 [5] Company Overview - LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies to improve vision in the U.S. [6] - Its product candidates, LNZ100 and LNZ101, are in Phase III clinical trials for treating presbyopia [6]

Core Viewpoint - LENZ Therapeutics is on track for the FDA review of its New Drug Application (NDA) for LNZ100, aimed at treating presbyopia, with a target action date set for August 8, 2025. The company has established a sales force and secured multiple international licensing agreements, indicating strong commercial potential for LNZ100 [1][2][3]. Company Developments - The NDA review by the FDA is progressing without significant issues, and no Advisory Committee Meeting is planned. The application is supported by positive results from the Phase 3 CLARITY study [3][4]. - LENZ has hired an 88-member sales force, ready to commence marketing activities immediately upon FDA approval [4]. - The company has executed international licensing agreements, including over $195 million in upfront and milestone payments, along with double-digit royalties on net sales [5][6]. Financial Highlights - As of June 30, 2025, LENZ reported cash, cash equivalents, and marketable securities totaling $209.6 million, which is expected to support operations through to post-launch positive cash flow [9]. - Research and Development (R&D) expenses increased to $9.1 million for Q2 2025, compared to $6.9 million in Q2 2024, primarily due to pre-approval manufacturing activities [10]. - Selling, General and Administrative (SG&A) expenses rose to $12.8 million for Q2 2025, up from $7.4 million in Q2 2024, driven by increased personnel costs and marketing expenses [11]. - The net loss for Q2 2025 was $14.9 million, compared to a net loss of $10.3 million in Q2 2024, reflecting the company's investment in commercialization efforts [12][17].

Core Insights - LENZ Therapeutics has achieved a significant milestone with the submission of a New Drug Application (NDA) for LNZ100 in China, marking the first regulatory submission outside the United States [1][4] - The NDA submission is backed by positive results from the Phase 3 JX07001 clinical trial, demonstrating significant improvements in near vision for patients with presbyopia [2][4] - Under the License and Collaboration Agreement with CORXEL, LENZ is eligible for up to $95 million in regulatory and sales milestones, along with tiered royalties on net sales in Greater China [3] Company Overview - LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first aceclidine-based eye drop for improving near vision in presbyopia patients [5] - LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, targeting a global population of approximately 1.8 billion people affected by presbyopia, including 128 million in the United States [5] - The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [5]

Core Insights - The "Catalyst Monitor: Q3 2025 Outlook" report provides forward-looking intelligence on significant catalyst events expected in Q3 2025, derived from interviews with key opinion leaders (KOLs) [1][3] - The report highlights 18 major catalyst events, including FDA approval decisions for various drugs targeting conditions such as adult growth hormone deficiency and wet age-related macular degeneration [2][4] Company and Industry Highlights - Ascendis Pharma's Skytrofa is under review for FDA approval for adult growth hormone deficiency [2] - PTC Therapeutics' sepiapterin is being evaluated for phenylketonuria, while Lenz Therapeutics' LNZ100 is aimed at treating presbyopia [2] - Eli Lilly's orforglipron is in ongoing clinical trials for obesity, and aTyr Pharma's efzofitimod is being studied for pulmonary sarcoidosis [3][4] - The report includes insights on the commercial impact of orforglipron in the GLP-1 market if approved, based on Phase III data [7] - KOLs assess the commercial potential of Lenz Therapeutics' LNZ100 in the context of existing non-pharmacological options for presbyopia [7] - Boehringer Ingelheim's Ofev is discussed regarding its potential expansion into pediatric interstitial lung disease amid safety concerns [7] Research Methodology - The report compiles predictive intelligence based on extensive research and exclusive interviews with KOLs, focusing on market-moving events expected in Q3 2025 [3][4] - It provides a comparative analysis of expected regulatory events, trial initiations, and completions in Q3 compared to the previous quarter [7]

Core Insights - LENZ Therapeutics and Laboratoires Théa have entered into an exclusive license and commercialization agreement for LNZ100, aimed at treating presbyopia in Canada, which includes over $70 million in upfront and milestone payments along with double-digit royalties on net sales [1][2][3] Company Overview - LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first aceclidine-based eye drop for improving near vision in presbyopia patients, with a PDUFA date set for August 8, 2025 [1][5] - Théa is an independent pharmaceutical company specializing in eye-care products, with a strong international presence and reported revenues of €970 million in 2024 [6] Market Potential - Presbyopia affects approximately 1.8 billion people globally and 128 million in the United States, indicating a significant market opportunity for LNZ100 [4][5] - The partnership with Théa is expected to enhance patient access to LNZ100 in Canada, a key market for Théa's international development [3][4]

LNZ100 Product & Clinical Trial Highlights - LNZ100, an aceclidine eye drop, aims to provide seamless vision for the majority of 128 million US presbyopes, with a potential launch in Q4 2025[3],[5],[48] - Clinical trials showed 71% of participants achieved ≥3-line improvement at 0.5 hours and 40% at 10 hours[3] - 84% of participants achieved a 4-line gain at some point during the efficacy studies, and 52% achieved a 5-line gain[36] - 41% of participants achieved at least 1 line of distance vision improvement[44] Market Opportunity & Commercial Readiness - The presbyopia market is estimated to be a $3B+ market[3],[5],[59] - Phase 3 patient surveys indicated 75% interest for continued use of LNZ100[3],[49] - ECPs survey indicated that 61% (~215) of their ~350 monthly patients are presbyopic[51],[52] - At a conservative 6% adoption rate or ~8 million users and a 42% refill rate, LNZ100 has blockbuster potential[59] Financial Position & Exclusivity - The company ended Q1 2025 with $194.1M in cash and anticipates >$190M at PDUFA, with cash to positive cash flow[3] - The product has market exclusivity based on a broad IP portfolio and potential new chemical entity (NCE) status[3] - The company has 8 granted patents (Exp 2034-2044) and 7 patents under review (Exp 2034-2044) in the US[64]

Company Overview - LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company focused on developing and commercializing the first and only aceclidine-based eye drop aimed at improving near vision in individuals with presbyopia [3] - The product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine [3] - Presbyopia affects an estimated 1.8 billion people globally and 128 million people in the United States [3] Upcoming Events - Company management will participate in several investor conferences, including: - William Blair 45 Annual Growth Stock Conference on June 3, 2025, in Chicago, IL, with a management presentation at 1:40pm EDT [1] - Jefferies Global Healthcare Conference on June 4-5, 2025, in New York City, NY, with a management presentation at 9:55am EDT [2] - Goldman Sachs 46 Annual Global Healthcare Conference on June 9, 2025, in Miami Beach, FL, featuring a fireside chat at 4:00pm EDT [2] - Live audio webcasts of the presentations will be available on the LENZ Therapeutics website, with replays accessible for 12 months following the events [2] Regulatory Milestones - The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [3] - The company is committed to commercializing an effective pharmaceutical solution for presbyopia that enhances vision for "all eyes, all day" [3]